Amarin Corporation(AMRN) - 2025 Q1 - Earnings Call Presentation

First Quarter 2025 Financial Results & Business Update Conference Call May 7, 2025 Forward-Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches,research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in ...